



#14
8/27/98
C. Stofle

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BY RE APPLICATION OF: -----

John Hargreaves Bateson et al.

APPLICATION NO.: 08/958,864

: Examiner: Sripada, P.

FILING DATE: October 20, 1997

: Group Art Unit: 1611

TITLE: Cephalosporins and Homologues,
Preparations and Pharmaceutical
Compositions

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists a reference cited by the applicant(s), a copy of which is enclosed.

The Examiner is requested to consider carefully the complete text of this reference in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the reference listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: August 19, 1998

Lorraine B. Ling
Lorraine B. Ling
Attorney for Applicant(s)
Reg. No. 35,251

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 573-2030

EXPRESS MAIL NO. EM 484850022US